Inspire Medical receives new CPT codes for sleep apnea device
Inspire Medical Systems (INSP) announced new CPT codes for its Inspire V sleep apnea device, effective January 1, 2028. The codes describe implantation procedures. CMS will determine Medicare payment values, with proposed valuations expected in July 2027. The device is FDA-approved and has treated over 140,000 patients.
How this was made
The 30-second read
Why it matters
New procedural codes can unlock reimbursement pathways, potentially expanding market adoption for Inspire's device.
Market read
First‑report of CPT code approval; modest but material for a niche medical‑device stock.
What to watch
Potential delays in CMS final payment rates and competition from alternative therapies.
Background
The article reports the AMA CPT Editorial Panel's approval of Category I codes for the Inspire V system, with CMS valuation to follow in 2027.
Ticker impact
Inspire Medical Systems received FDA‑approved CPT codes for its Inspire V sleep apnea device, a first‑time procedural coding that could boost future reimbursements.
potential upside as reimbursement prospects improve
Codes are scheduled for 2028, so the impact is forward‑looking; investors may price in incremental revenue growth.
Market effects
May lift sentiment for sleep‑apnea device makers and broader medical‑technology reimbursement outlook.
U.S. healthcare reimbursement environment sees a modest positive tweak.
Limited; primarily affects U.S. insurers and providers.
Counterpoint
If CMS valuation is low, the codes may not translate into meaningful revenue, limiting upside.
Key entities
- companyInspire Medical Systems
Developer of the Inspire V sleep apnea therapy device.
- organizationAmerican Medical Association
CPT Editorial Panel that approved the new codes.
